Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: For patients receiving quad induction, MRD<10-5 was 29% (<10-6 15%) and 59% post-ASCT (<10-6 45%); ASCT lowered MRD >1 log in 69%; quad (vs. triplet) did not reduce effect of ASCT; reduction in most pronounced in high-risk patients.”

“Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy”

Authors: Susan Bal, Tylan Magnusson, Gayathri Ravi, Smith Giri, Kelly Godby, Binod Dhakal, Natalie Callander, Rebecca Silbermann, Bhagirathbhai Dholaria, Vishnu Reddy, Luciano Costa.

Myeloma Paper of the Day, April 25th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.